Oncology · Pancreatic CancerOtherclinicalmid-term

UBE2C identified as a key driver in pancreatic cancer via PI3K/Akt/mTOR pathway

Importance8/ 10

ActionInvestigate

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 6:34:03 PM

Assessment confidence: 54% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The identification of UBE2C as a key driver in pancreatic cancer progression highlights a significant opportunity for novel therapeutic interventions. This could reshape treatment paradigms and necessitate a reevaluation of existing therapies targeting the PI3K/Akt/mTOR pathway. Regulatory context from MHRA (MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer) supports the near-term read. Assessment grounded in 23 ranked evidence items (5 high-relevance).

Strategic Assessment

UBE2C in drug development strategies and biomarker identification for pancreatic cancer. The strongest clinical anchor is A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (ClinicalTrials.gov), sponsor/company relevance (merck). In Oncology · Pancreatic Cancer, 5 regulatory and 4 competitive items passed relevance filtering for UBE2C.

Competitive Pressure

The most relevant competitive pressure comes from TGFA identified as key regulator in cervical cancer progression via DSG2 interaction (Humanexa Signals) — moderate corpus alignment. Secondary pressure from RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression. Identifying UBE2C as a therapeutic target may shift focus towards novel treatments in pancreatic cancer, impacting existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer (MHRA). Regulatory pathway relevance (bla). Relevant agencies in corpus: MHRA, FDA. The emergence of UBE2C as a biomarker may influence regulatory pathways for drug approvals and necessitate updates to clinical trial designs focusing on this target.

Key Risks

Elevated medium regulatory exposure for UBE2C could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

If UBE2C-targeted therapies prove effective, they could capture significant market share in the oncology space, particularly for pancreatic cancer, which currently has limited treatment options.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Lead sponsor: Jazz Pharmaceuticals. Collaborators: Jazz Pharmaceuticals Ireland Limited.
UBE2C in drug development strategies and biomarker identification for pancreatic cancer.

What Would Change This Assessment

This becomes more urgent if Monitor developments in UBE2C-targeted therapies and clinical trials assessing its role as a biomarker.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de N
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of the Life Changes Experienced by Patients With Pancreatic Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Nursing-led Communication Using Mobile Health Information in Breast Cancer Patients Undergoing Concurrent Chemotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

TGFA identified as key regulator in cervical cancer progression via DSG2 interaction
Humanexa Signalsmedium relevance
Moderate corpus alignment
RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression
Humanexa Signalsmedium relevance
Moderate corpus alignment
KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition
Humanexa Signalsmedium relevance
Moderate corpus alignment
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedhigh relevance
Entity match (ube2c)
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microwave hyperthermia enhances radiosensitivity of highly invasive non-small cell lung cancer cells via inhibiting Sonic Hedgehog signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

UBE2C
clinical trial programs
pancreatic cancer therapies
oncology drug development

Commercial impact

high

If UBE2C-targeted therapies prove effective, they could capture significant market share in the oncology space, particularly for pancreatic cancer, which currently has limited treatment options.

Regulatory impact

medium

The emergence of UBE2C as a biomarker may influence regulatory pathways for drug approvals and necessitate updates to clinical trial designs focusing on this target.

What to watch

Monitor developments in UBE2C-targeted therapies and clinical trials assessing its role as a biomarker.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.